Sign In
Buy SONN
$1.26
+0 (+0%)
At Close: Feb 27, 2026
Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
03:00pm, Wednesday, 24'th Jul 2024
Watch the "What This Means" segment here FRENCHTOWN, NJ / ACCESSWIRE / July 24, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtu
PRINCETON, N.J., July 24, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeut
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
08:00am, Tuesday, 28'th May 2024
PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic d
The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
04:15pm, Tuesday, 14'th May 2024
Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived Interleukin 12 in healthy volunteers Announced early safety data from the
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
07:00am, Monday, 06'th May 2024
PRINCETON, NJ / ACCESSWIRE / May 6, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be participating in the
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
09:00am, Friday, 03'rd May 2024
Minneapolis, Minnesota--(Newsfile Corp. - May 3, 2024) - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be partic
PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs
Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‑080 was reviewed by the study's Data Safety Monitoring Board (DSMB) The adverse event profile and tolerabili
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
04:05pm, Thursday, 29'th Feb 2024
PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today t
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
07:30am, Wednesday, 14'th Feb 2024
Successfully raised approximately $4.55 million in gross proceeds through an underwritten public offering Extensive preclinical data on SON-1210 published in Frontiers in Immunology Received approval
PRINCETON, NJ / ACCESSWIRE / December 21, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today t
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
04:15pm, Thursday, 14'th Dec 2023
PRINCETON, NJ / ACCESSWIRE / December 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic dr
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
07:30am, Tuesday, 31'st Oct 2023
Following the recent completion of a $4.55 million financing, Sonnet projects cash runway into the calendar year third quarter of 2024 The company is focused on its business development initiatives an
Why Is Sonnet BioTherapeutics (SONN) Stock Down 33% Today?
08:42am, Wednesday, 25'th Oct 2023
Sonnet BioTherapeutics (NASDAQ: SONN ) stock is falling on Wednesday after the biotechnology company revealed details of a public share offering. That public stock offering has Sonnet BioTherapeutics
